title: Impaired blood rheology by remnant-like lipoprotein particles: studies in patients with fatty liver disease.
abstract: Fatty liver disease (FLD) characterised by a high plasma levels of lipoproteins and remnant-like lipoproteins (RLP) is a risk factor for impaired microvascular blood flow, endothelial cell dysfunction and atherosclerosis. Using an immunoseparation technique with a gel mixture containing human monoclonal antibodies to apo A-I and apo B-100, we separated and measured RLP cholesterol (RLP-C) levels which reflect RLP in patients with FLD (n=20). Whole blood transit time (TT) was determined by a microchannel method (MC-FAN) which allows blood flow to be viewed via a microscope connected to an image display unit. RLP-C levels were higher (P<0.01) in FLD, 15.6 +/- 1.0 mg/dl compared with 4.8 +/- 0.5 mg/dl for controls (n=20). Similarly, TT was longer (P<0.01) in FLD, 284.5 +/- 26.1 sec/100 microl compared with 82.8 +/- 1.0 sec/100 microl for controls. Since the liver is a major site for RLP formation and degradation, it is affected to a greater extent in patients with FLD. It is likely that high levels of RLP can impair microvascular perfusion in the liver tissue and contribute to the development and progression of FLD.
authors.affiliation: Institute of Geriatrics, Tokyo Women's Medical University, Tokyo, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Kurihara
authors.forename: S
authors.initials: S
authors.lastname: Deguchi
authors.forename: J
authors.initials: J
authors.lastname: Kato
authors.forename: M
authors.initials: M
authors.lastname: Furakawa
authors.forename: M
authors.initials: M
authors.lastname: Tsuchiya
authors.forename: M
authors.initials: M
authors.lastname: Akimoto
authors.forename: H
authors.initials: H
authors.lastname: Ishiguro
authors.forename: H
authors.initials: H
authors.lastname: Hashimoto
authors.forename: A
authors.initials: A
authors.lastname: Niimi
authors.forename: A
authors.initials: A
authors.lastname: Maeda
authors.forename: M
authors.initials: M
authors.lastname: Shigemoto
authors.forename: K
authors.initials: K
authors.lastname: Yamashita
authors.forename: A
authors.initials: A
authors.lastname: Kawakami
authors.forename: K
authors.initials: K
authors.lastname: Umemura
authors.forename: M
authors.initials: M
authors.lastname: Nakashima
authors.forename: T
authors.initials: T
authors.lastname: Nakano
authors.forename: A R
authors.initials: AR
authors.lastname: Saniabadi
mesh_terms: D015762:2-Chloroadenosine / Q000494:pharmacology; D000911:Antibodies, Monoclonal; D016632:Apolipoprotein A-I / Q000276:immunology; D053299:Apolipoprotein B-100; D001055:Apolipoproteins B / Q000276:immunology; D001783:Blood Flow Velocity / Q000187:drug effects; D016022:Case-Control Studies; D002784:Cholesterol / Q000097:blood* / Q000276:immunology / Q000494:pharmacology*; D002846:Chromatography, Affinity; D005234:Fatty Liver / Q000097:blood / Q000209:etiology; D018056:Hemorheology / Q000187:drug effects*; D006801:Humans; D007163:Immunosorbent Techniques; D008074:Lipoproteins / Q000097:blood* / Q000276:immunology / Q000494:pharmacology*; D013927:Thrombosis / Q000209:etiology; D014280:Triglycerides / Q000097:blood* / Q000276:immunology / Q000494:pharmacology*
chemical_list: D000911:Antibodies, Monoclonal; D016632:Apolipoprotein A-I; D053299:Apolipoprotein B-100; D001055:Apolipoproteins B; D008074:Lipoproteins; D014280:Triglycerides; C112017:remnant-like particle cholesterol; D015762:2-Chloroadenosine; D002784:Cholesterol